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Subjects or Study Selection:  
This systematic review compared the efficacy of different antibiotic prophylaxis (AP) 
regimens for reducing the incidence of post-invasive dental procedure bacteremia. 
The key words “prevention”, “bacteremia” and “dental procedure” were used to 
search ClinicalKey, Cochrane CENTRAL, Embase, ProQuest, PubMed, 
ScienceDirect, Web of Science and ClinialTrials.gov from inception to December 4, 
2018, and identified 217 citations. After exclusions, 24 studies, covering 2,147 
participants, were identified that met the inclusion criteria of reporting randomized 
controlled trials (RCT) of placebo- or active-controlled design (comparison of 
different prophylactic interventions) and included adult or pediatric participants. To 
make these comparisons, a network meta-analysis (NMA) also known as a multiple 
treatment comparison meta-analysis was performed. This is a meta-analysis in 
which multiple treatments, that is, three or more, are compared using both direct 
comparisons of interventions within RCT and indirect comparisons across trials 
based on a common comparator.1 
Key Study Factor: 
The main purpose of AP before invasive dental procedures is to prevent infective 
endocarditis (IE) in those at high-risk of the condition. It may also be used to prevent 
other distant site infections e.g. prosthetic joint infections, in those at risk. Ideally, the 
efficacy of AP would be tested in RCT that compared any reduction in the incidence 
of IE following invasive dental procedures performed with and without AP cover. 
Since the incidence of IE is low, and studies would need to be performed on 
individuals at high-risk of IE, ethical concerns and the size and cost of such studies 
have precluded any to date. As a surrogate for such studies, RCT measuring the 
effect of AP on the incidence of bacteremia following invasive dental procedures 
have been used instead, and these are the type of study evaluated in this systematic 
review. The data, therefore, while important, highly clinically relevant and among the 
best currently available, may not directly translate to efficacy in preventing IE. 
Main Outcome Measure: 
The main outcome evaluated was the reduction in incidence of post-invasive dental 
procedure bacteremia that occurred with different AP regimens. 
Main Results:  
The study found that the oral AP regimen that was most effective in reducing overall 
post-procedural bacteremia was 3g of amoxicillin (Odds ratio [OR] 0.1; 95% 
confidence interval [CI], 0.02-0.44). An OR <1 indicates that there is less incidence 
of post-procedural bacteremia than with placebo/control. The smaller the OR, the 
more effective that regimen is in reducing post-procedural bacteremia, and the 
reduction is likely to be significant if the CI does not include 1. The next most 
effective regimen was 2g of amoxicillin (OR, 0.16, 95% CI, 0.05-0.54). For 
intravenous regimens, 1,000/200 mg of amoxicillin/clavulanate provided the least 
incidence of post-procedural bacteremia (OR, 0.03, 95% CI, 0.00-0.63). Some other 
intravenous regimens were also effective. 
Conclusions: 
This NMA suggests that 3g oral amoxicillin and 1,000/200 mg intravenous 
amoxicillin/clavulanate are likely the best antibiotic prophylaxis interventions for 
preventing post invasive dental procedure bacteremia. 
 
Commentary and Analysis 
Infective endocarditis (IE) is an infection of heart valves. Affected individuals are 
acutely ill and often require intensive care. Treatment is with intravenous antibiotics 
but ~50% also require surgical replacement of one or more heart valves. First year 
mortality is ~30% and survivors suffer serious lifelong complications and increased 
risk of further IE.2 
Oral bacteria account for 35-45% of IE cases.3 However, there is controversy about 
the contribution made by invasive dental procedures and daily activities, e.g. 
toothbrushing, flossing and mastication, to the development of oral bacterial IE.4 
Currently, apart from maintaining good oral hygiene, the only active IE prevention 
measure recommended by most guideline committees around the world is the use of 
antibiotic prophylaxis (AP) before invasive dental procedures for those at highest-
risk, even though there are no randomized controlled trial (RCT) data to support its 
use.3, 4 This is because ethical concerns and the size and cost of RCT has prevented 
their use to test AP efficacy to date. As a consequence, researchers have had to 
resort to less compelling observational studies and RCT using surrogate markers for 
IE, such as post-procedural bacteremia, to evaluate AP efficacy. 
Bacteremia studies are not without their problems. Ideally, one would like to know 
how much the number of oral bacteria with the capacity to cause IE that are released 
into the circulation following a dental procedure is reduced by AP compared to no or 
placebo prophylaxis. However, techniques that can quantify the bacterial load and 
identify those species that cause IE have only become available comparatively 
recently. Hence, most bacteremia studies report not the size but the frequency with 
which a bacteremia was detected, i.e. how often a bacteremia exceeded the lower 
detection limits of the method used. Different methods have different lower detection 
limits, and most studies have not focused on those oral bacteria capable of causing 
IE. Therefore, there are significant methodological difference between studies. 
A recent systematic review and meta-analysis of 21 AP clinical trials found AP to be 
effective in reducing overall post-procedural bacteremia (risk ratio 0.53, 95% CI 0.49-
0.57), but noted that methodological issues mean that post-procedural bacteremia 
may not always be a good surrogate endpoint for IE.5 Nonetheless, this and the 
current study6 both conclude that AP is likely to be effective in reducing post-
procedural bacteremia. The current study goes a step further though, by performing 
a NMA to compare the efficacy of different AP regimens in reducing post-procedural 
bacteremia.6 Although the results should be treated with some caution, they will be 
of considerable interest to clinicians and guideline committees world-wide. 
The finding that amoxicillin is the most effective oral AP preparation will reassure 
many. The finding that amoxicillin 3g may provide better protection than 2g, 
however, should cause guideline committees that recommend the lower dose to 
revaluate their dosage recommendations, particularly as the higher dose is arguably 
less likely to generate antibiotic resistance and has been shown to be associated 
with a very low risk of adverse-reactions.7 
Data from this study is less reassuring about the efficacy of AP alternatives for those 
allergic to amoxicillin. Neither clindamycin 600mg (OR 0.61, 95% CI 0.21-1.78) nor 
azithromycin 500mg (OR 0.35, 95% CI 0.07-1.68) showed significant overall efficacy. 
This reinforces the importance of labelling only those with true penicillin allergy as 
penicillin allergic, particularly given the worse adverse-reaction profile of amoxicillin 
alternatives, specifically clindamycin.7, 8 
For intravenous use, 1,000/200mg amoxicillin/clavulanate (OR 0.03, 95% CI 0.00-
0.63) had greatest overall efficacy, although other IV regimens were also effective. 
NMA is a complex methodology that allows multi-directional comparisons to be made 
between treatment based on studies that will largely have comparisons only made 
between one treatment and placebo, or one treatment and another.1 This can be 
incredibly helpful for clinicians who have to choose between multiple treatment 
options, many of which will not have been formally tested in a study. However, NMA 
methodology assumes homogeneity of methodology between studies and this may 
not be the case when different dental procedures, methods of anaesthesia/analgesia 
and patient populations have been studied, and different bacteremia detection 
methods used. The 95%CI will also be larger for AP regimens where few studies 
exist. A degree of caution should be exercised, therefore, when interpreting the 
results. Nonetheless, the data on overall AP efficacy is compelling and particularly 
strong for oral amoxicillin efficacy. 
In conclusion, this study provides important new evidence that oral amoxicillin and IV 
amoxicillin/clavulanate are likely the most effective prophylactic interventions for 
reducing post-invasive dental procedure bacteremia. 
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